Copolymer-1 as a potential therapy for mild cognitive impairment

Keyphrases

• Copolymer-1 100%
• Mild Cognitive Impairment 100%
• Potential Therapy 100%
• Brain-derived Neurotrophic Factor 50%
• Memory Impairment 33%
• Neuroinflammation 33%
• Amnestic Mild Cognitive Impairment (aMCI) 33%
• Dementia 33%
• Oxidative Stress 16%
• Immunization 16%
• Neurogenesis 16%
• Amino Acids 16%
• Anti-inflammatory Properties 16%
• Synaptic Plasticity 16%
• Cognitive Impairment 16%
• Factor Level 16%
• Therapeutic Effect 16%
• Alzheimer's Disease 16%
• Prodromal Stage 16%
• Cerebrovascular Disease 16%
• Anti-inflammatory Phenotype 16%
• Neuronal Loss 16%
• Relapsing-remitting multiple Sclerosis 16%
• Approved Drugs 16%
• Memory Consolidation 16%
• Long-term Potential 16%
• Amnestic 16%
• Glatiramer Acetate 16%
• Synaptic Memory 16%
• Synthetic Polypeptide 16%
• Neurotrophins 16%
• Amyloid Deposition 16%
• Cholinergic Dysfunction 16%
• Immunomodulation 16%
• Patients with Cognitive Impairments 16%
• Intracellular Neurofibrillary Tangles 16%

Neuroscience

• Glatiramer Acetate 100%
• Mild Cognitive Impairment 100%
• Brain-Derived Neurotrophic Factor 37%
• Cognitive Disorders 25%
• Anti-Inflammatory 25%
• Memory Disorder 25%
• Memory Consolidation 12%
• Oxidative Stress 12%
• Alzheimer's Disease 12%
• Amino Acid 12%
• Neurogenesis 12%
• Synaptic Plasticity 12%
• Cholinergic 12%
• Neurotrophin 12%
• Relapsing Remitting Multiple Sclerosis 12%
• Cerebrovascular Disease 12%
• Polypeptide 12%
• Amyloid Protein 12%
• Neurofibrillary Tangle 12%